Corixa Corporation Announces Stockholder Approval of Merger with GlaxoSmithKline

Corixa Corporation (Nasdaq:CRXA) today announced that
its stockholders have adopted the merger agreement pursuant to which
Corixa will be merged with and into a wholly owned subsidiary of
SmithKline Beecham Corporation (d/b/a/ GlaxoSmithKline) and Corixa
stockholders will receive $4.40 in cash for each share of common
stock, $517.65 in cash for each share of Series A Preferred Stock and
$172.01 for each share of Series B Preferred Stock. On April 29, 2005,
Corixa and GlaxoSmithKline announced the signing of the merger
agreement.
   Adoption of the merger agreement by Corixa's stockholders
satisfies one of the conditions to the completion of the transaction.
Corixa anticipates that the merger will occur later today, subject to
the satisfaction or waiver of all other closing conditions to the
merger.

   About Corixa and Forward Looking Statements

   Corixa is a biopharmaceutical company developing vaccine adjuvants
and immunology based products that manage human diseases. Corixa's
products are currently in multiple clinical development programs,
including several that have advanced to and through late stage
clinical trials. The company partners with numerous developers and
marketers of pharmaceuticals, targeting products that are Powered by
Corixa(TM) technology with the goal of making its potential products
available to patients around the world. Corixa was founded in 1994 and
is headquartered in Seattle, with additional operations in Hamilton,
Montana. For more information, please visit Corixa's Web site at
www.corixa.com.

   This press release contains forward-looking statements, including
statements regarding the outcome and expected completion date of the
proposed transaction between Corixa and GlaxoSmithKline.
Forward-looking statements are based on the opinions and estimates of
management at the time the statements are made. They are subject to
certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements
expressed or implied by such statements. Factors that could affect
Corixa's actual results include, but are not limited to, the risk that
the acquisition by GSK does not close as a result of a failure to
satisfy the closing conditions or otherwise and the "Factors Affecting
Our Operating Results, Our Business and Our Stock Price," described in
Corixa's Quarterly Report on Form 10-Q for the quarter ended March 31,
2005, copies of which are available from the company's investor
relations department. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this release.